Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Net Income (2017 - 2025)

Historic Net Income for Integra Lifesciences Holdings (IART) over the last 16 years, with Q3 2025 value amounting to -$5.4 million.

  • Integra Lifesciences Holdings' Net Income rose 4947.17% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$495.3 million, marking a year-over-year decrease of 746930.01%. This contributed to the annual value of -$6.9 million for FY2024, which is 11025.08% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Net Income is -$5.4 million, which was up 4947.17% from -$484.1 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Net Income peaked at $52.9 million during Q4 2022, and registered a low of -$484.1 million during Q2 2025.
  • For the 5-year period, Integra Lifesciences Holdings' Net Income averaged around -$5.5 million, with its median value being $19.8 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 960352.3% in 2021, then crashed by 380318.5% in 2025.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Net Income stood at $45.4 million in 2021, then grew by 16.66% to $52.9 million in 2022, then crashed by 62.54% to $19.8 million in 2023, then dropped by 2.01% to $19.4 million in 2024, then tumbled by 127.81% to -$5.4 million in 2025.
  • Its Net Income was -$5.4 million in Q3 2025, compared to -$484.1 million in Q2 2025 and -$25.3 million in Q1 2025.